Transmucosal Drug Delivery Devices Market Report 2024

The transmucosal drug delivery devices market size has grown strongly in recent years. It will grow from $46.16 billion in 2023 to $50.24 billion in 2024 at a compound annual growth rate (CAGR) of 8.8%. The growth observed in the historical period can be attributed to several factors, the demand for rapid relief from angina, the effectiveness of sublingual delivery for swift absorption into the bloodstream, the preference for bypassing gastrointestinal degradation, advancements in the development of buccal tablets, and the necessity for non-invasive delivery of peptides and proteins.

The transmucosal drug delivery devices market size is expected to see strong growth in the next few years. It will grow to $71.69 billion in 2028 at a compound annual growth rate (CAGR) of 9.3%. The anticipated growth in the forecast period can be attributed to several factors, including the advancement of smart drug delivery systems, a rise in the prevalence of chronic diseases, increasing emphasis on personalized medicine, a growing aging population with higher medication requirements, and heightened awareness among healthcare providers and patients. Key trends expected in this period include the expansion of therapeutic applications for drug delivery systems, customization of devices to meet the needs of personalized medicine, adherence to regulatory approvals and guidelines, penetration into emerging markets, development of eco-friendly devices, and innovation in formulation technologies.

The anticipated growth of the transmucosal drug delivery devices market is expected to be driven by the growing prevalence of chronic diseases. Chronic diseases are long-lasting conditions that progress slowly and require ongoing medical management to control symptoms and prevent complications. Factors contributing to the rise in chronic diseases include lifestyle choices, aging populations, environmental factors, challenges within healthcare systems, and urbanization trends. Transmucosal drug delivery devices play a crucial role in the management of chronic diseases by providing controlled and efficient delivery of medications. This ensures sustained therapeutic levels, enhances symptom management, and improves patient adherence to treatment regimens. For example, according to a July 2021 report from the International Diabetes Federation (IDF), approximately 537 million people worldwide were living with diabetes. The number of cases has been steadily increasing, with projections suggesting that by 2045, around 783 million people will have diabetes - an increase of 46%. This significant rise underscores how the increasing prevalence of chronic diseases is a key driver behind the growth of the transmucosal drug delivery devices market.

Leading companies in the transmucosal drug delivery devices sector are actively pursuing innovative solutions such as proprietary transdermal patch delivery platforms, which are designed to improve drug absorption, enhance patient compliance, and offer convenience. These platforms utilize specialized technologies owned by companies to administer medications through the skin, ensuring controlled release and optimized therapeutic outcomes. For example, in January 2024, Starton Therapeutics Inc., a US-based biotechnology firm, introduced STARSILON, a novel proprietary transdermal patch delivery platform. This platform is specifically designed to deliver difficult-to-formulate active pharmaceutical ingredients (APIs) over an extended period, thereby expanding the options for transdermal drug delivery and enhancing therapeutic efficacy through sustained release mechanisms.

In April 2023, Difgen Pharmaceuticals, an India-based pharmaceutical company, acquired Aveva Drug Delivery Services for an undisclosed sum. This strategic acquisition is intended to bolster Difgen Pharmaceuticals' drug delivery capabilities and incorporate advanced technologies into its pharmaceutical product portfolio. Aveva Drug Delivery Services, based in the US, specializes in manufacturing transdermal delivery systems (TDS) and oral dissolvable films (ODF).

Major companies operating in the transmucosal drug delivery devices market are Johnson & Johnson, Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, Becton Dickinson and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Catalent Inc., AptarGroup, Glenmark Pharmaceuticals Limited, Stevanato Group S.p.A, Lifevision Healthcare Private Limited, Noven Pharmaceuticals, SAVA Healthcare Limited, Antares Pharma Inc., Kaizen Pharmaceuticals Pvt. Ltd., Lucky Pharma Pvt. Ltd., Maya Biotech Pvt. Ltd, AdvaCare Pharma LLP, Satsuma Pharmaceuticals Inc., Biophar Lifesciences Private Limited, Fibovil Pharmaceuticals Private Limited, Slan Medicinal Holdings Ltd.

North America was the largest region in the transmucosal drug delivery devices market in 2023. The regions covered in the transmucosal drug delivery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the transmucosal drug delivery devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Transmucosal drug delivery devices are medical instruments designed to administer drugs through mucous membranes, such as those found in the mouth, nose, or rectum, allowing for rapid absorption into the bloodstream. These devices are particularly useful for delivering medications that are poorly absorbed by the gastrointestinal tract or require swift onset of action, such as pain relief or hormone therapy. Their primary function is to circumvent the digestive system, offering a direct and efficient route for drug delivery.

The two main categories of transmucosal drug delivery devices are passive transmucosal drug delivery and active transmucosal drug delivery. Passive transmucosal drug delivery involves the absorption of drugs through mucous membranes without external energy or active transport mechanisms. Various types of products include buccal tablets, oral sprays, sublingual films, wafers, gels, medicated confectionery, among others, used for treating conditions such as pain management, addiction, and hormonal therapies. End users include academic and research institutions, pharmaceutical and biotechnology firms, diagnostic laboratories, and hospitals.

The transmucosal drug delivery devices research report is one of a series of new reports that provides transmucosal drug delivery devices market statistics, including the transmucosal drug delivery devices industry's global market size, regional shares, competitors with a transmucosal drug delivery devices market share, detailed transmucosal drug delivery devices market segments, market trends, and opportunities, and any further data you may need to thrive in the transmucosal drug delivery devices industry. This transmucosal drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The transmucosal drug delivery devices market consists of sales of sublingual sprays, nasal drops, rectal suppositories, and sublingual tablets. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.